FDA grants emergency use authorization to Eli Lilly’s COVID-19 antibody treatment
The United States Food & Drug Administration (FDA) has granted emergency use authorization (EUA) of Eli Lilly’s COVID-19 antibody treatment (bamlanivimab) for mild to moderate COVID-19 infections. The drug, infused as a one-time dose in a hospital or other healthcare setting, is intended to be given to patients as soon as they receive a positive COVID-19 test within 10 days of the onset of symptoms, and may be effective at preventing the disease from advancing to a more severe stage. The EUA is not the same as full approval – it requires the drug be given in a healthcare setting and that health professionals report any adverse events.
Published: November 10, 2020
CTV NewsRead Article